Close

Goldman Sachs Starts Mirati Therapeutics (MRTX) at Buy

April 16, 2020 4:41 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter initiates coverage on Mirati Therapeutics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login